Chaffin Luhana Continues Yaz, Yasmin and Ocella Lawsuit Investigations
March 12th, 2010Chaffin Luhana LLP, a mass tort litigation firm located in New York and representing consumers nationwide, announces their continued investigation of Yaz and Yasmin lawsuits. To date, over 600 Yaz, Yasmin and Ocella lawsuits have been filed in the multi-district litigation (MDL), which has been established in the United States District Court for the Southern District of Illinois. The MDL consolidates all of the Yaz, Yasmin and Ocella cases filed across the country in one court. Judge Herndon, who presides over the MDL, has appointed only 17 attorneys to the Plaintiffs’ Steering Commit...
Albany Law School Journal of Science & Technology Publishes Eric Chaffin’s Presentation on Off-Label Marketing of Drugs and Devices
March 9th, 2010Chaffin Luhana LLP announces the publication of partner Eric Chaffin’s presentation “Off-Label Use from an Injured Consumers’ Perspective” in the Albany Law Journal of Science & Technology. This volume of the nationally ranked legal journal is a transcript of the presentations made on March 27, 2009 at Albany Law School’s symposium on the issue of off-label drug use entitled “Regulating the Cure: Topics Arising out of the Prescription of Drugs Off-Label.” The symposium consisted of three panels on the following topics: off-label drug use and bio-ethics, curren...
Chaffin Luhana Applauds Procter & Gamble’s Addition of Zinc Warning to Fixodent Website
March 1st, 2010Procter & Gamble(P&G), the manufacturer of the popular denture adhesive cream Fixodent, recently added a warning on their denture cream consumer website “DentureLiving.Com” alerting users to the potentially dangerous side effects of the zinc in their denture cream. Chaffin Luhana, a boutique plaintiffs’ firm in New York, applauds P&G’s acknowledgment of this potentially dangerous ingredient, however urges the company to take larger strides to prevent consumer harm. The firm currently represents over 50 consumers who have used either Fixodent, or its competitor, GlaxoSmith...
